Tagrisso, with the addition of chemotherapy, showed favourable trend in overall survival in EGFR-mutated advanced lung cancer
Results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated…